Literature DB >> 18767145

Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression?

Lauréline Deluche1, Sami Joha, Sélim Corm, Agnès Daudignon, Sandrine Geffroy, Sabine Quief, Céline Villenet, Jean-Pierre Kerckaert, Jean-Luc Laï, Claude Preudhomme, Catherine Roche-Lestienne.   

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the presence in leukemic stem cells of the Philadelphia chromosome (Ph) and the formation of the BCR-ABL1 fusion. Untreated, the disease progresses to accelerate phase and blast crisis in which hematopoietic differentiation has become arrested. CML progression is frequently associated with cytogenetic evidence of clonal evolution, defined as additional chromosomal aberrations. We here report a CML resistant to tyrosine kinase inhibitors that rapidly progressed to blastic phase. At this time, array CGH performed on CD34(+) cells revealed cryptic partial deletions of both PRDM16 and RUNX1 and duplication of the der(21) chromosome. These genomic rearrangements were confirmed by FISH with probes targeting the deletion on chromosome 21 (24 kb), and with BAC probes flanking the deletion on 1p36 (220 kb). However, no cryptic t(1;21)(p36;q22) and/or RUNX1-PRDM16 were detected, suggesting that these deletions are the residual hallmarks of a more complex mechanism of chromosomal rearrangement, as indicated by the additional inversion of the region bounded by 1p36.32 and 1p36.12 breaks. At the molecular level, these abnormalities lead to the overexpression of the PR-domain negative oncogenic isoform of PRDM16, associated with two deleted copies within the runt domain of C-teminal aberrant RUNX1. These events are not detectable by conventional cytogenetic and molecular strategies, and may be of underestimated frequency in disease progression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18767145     DOI: 10.1002/gcc.20611

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  7 in total

Review 1.  Chronic myeloid leukemia: mechanisms of blastic transformation.

Authors:  Danilo Perrotti; Catriona Jamieson; John Goldman; Tomasz Skorski
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

Review 2.  Selection of therapy: rational decisions based on molecular events.

Authors:  Jamshid S Khorashad; Michael W N Deininger
Journal:  Hematol Oncol Clin North Am       Date:  2011-10       Impact factor: 3.722

3.  Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia.

Authors:  Norio Shiba; Kenichi Yoshida; Yusuke Hara; Genki Yamato; Yuichi Shiraishi; Hidemasa Matsuo; Yusuke Okuno; Kenichi Chiba; Hiroko Tanaka; Taeko Kaburagi; Masanobu Takeuchi; Kentaro Ohki; Masashi Sanada; Jun Okubo; Daisuke Tomizawa; Tomohiko Taki; Akira Shimada; Manabu Sotomatsu; Keizo Horibe; Takashi Taga; Souichi Adachi; Akio Tawa; Satoru Miyano; Seishi Ogawa; Yasuhide Hayashi
Journal:  Blood Adv       Date:  2019-10-22

Review 4.  Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state.

Authors:  Tomasz Skorski
Journal:  Leuk Lymphoma       Date:  2011-02

Review 5.  Genetic mechanisms of chronic myeloid leukemia blastic transformation.

Authors:  Tomasz Skorski
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

Review 6.  Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.

Authors:  Anna M Eiring; Michael W Deininger
Journal:  Genome Biol       Date:  2014-09-17       Impact factor: 13.583

Review 7.  Multifaceted Role of PRDM Proteins in Human Cancer.

Authors:  Amelia Casamassimi; Monica Rienzo; Erika Di Zazzo; Anna Sorrentino; Donatella Fiore; Maria Chiara Proto; Bruno Moncharmont; Patrizia Gazzerro; Maurizio Bifulco; Ciro Abbondanza
Journal:  Int J Mol Sci       Date:  2020-04-10       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.